Table 2.
Clinical trials comparing immunogenicity of two versus three doses of HPV vaccines in females.
| Trial Number | Study Location | Vaccine | Age | Formulation | Dose Timeline | Results |
|---|---|---|---|---|---|---|
| NCT00541970 | Canada and Germany | bHPV | 9-14, 15-19, and 20-25 years | licensed vs increased antigen content | (0, 6 months) or (0, 2 months) vs (0, 2, 6 months) | Two-dose schedule in girls 9-14 years was non-inferior to three-dose schedule in women 15-25 years |
| NCT01717118 | Mexico | bHPV | 9-10 years and 18-24 years | licensed | (0, 6, 60 months) vs (0, 1, 6 months) | Two-dose schedule in girls 9-10 years was non-inferior to three-dose schedule in women 18-24 years |
| NCT01381575 | Germany, Canada, Italy, Taiwan, and Thailand | bHPV | 9-14 years vs 15-25 years | licensed | (0, 6 months or 0, 12 months) vs (0, 1, 6 months) | ongoing |
| NCT00501137 | Canada | qHPV | 9-13 years and 16-26 years | licensed | (0, 6 months) vs (0, 2, 6 months) | At 36 months, antibody responses to all four HPV types were non-inferior for both two- and three-dose regimens among 9-13-year-old girls compared to three-dose regimen in women ages 16-26. |
| NCT00923702 | India | qHPV | 10-18 years | licensed | (0, 6 months) vs (0, 2, 6 months) | Study stopped |
*Note: bHPV=bivalent HPV vaccine (HPV genotypes 16/18). qHPV= quadrivalent HPV vaccine (HPV genotypes 6/11/16/18).